Characterization of antibodies specific for hemagglutinin and neuraminidase proteins of the 1918 and 2009 pandemic H1N1 viruses

Vaccine

Volumn 29, Issue 2, 2010, Pages 183-190

  Liu, Yuan ^a   Liu, Xiaoqing ^a   Fang, Jing ^a,b   Shen, Xiaona ^c   Chen, Wei ^c   Lin, Xiaojing ^d   Li, Huaifang ^b   Tan, Wenjie ^d   Wang, Yue ^d   Zhao, Ping ^a   Qi, Zhongtian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c Fujian Center for Disease Control and Prevention   (China)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Cross neutralizing; Effect of anti NA antisera; Preexisting immunity

Indexed keywords

HEMAGGLUTININ ANTIBODY; INFLUENZA VIRUS HEMAGGLUTININ; NEURAMINIDASE ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; CYTOPATHOLOGY; FEMALE; HUMAN; HUMAN CELL; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; PLASMID; PRIORITY JOURNAL; PSEUDOTYPING; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CROSS PROTECTION; CROSS REACTIONS; CYTOPATHOGENIC EFFECT, VIRAL; DOGS; FEMALE; GENETIC VECTORS; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NEURAMINIDASE; NEUTRALIZATION TESTS; PLASMIDS; VACCINES, DNA; VIRAL PROTEINS;

EID: 78649692438     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.059     Document Type: Article

References (59)

1. Combadiere B., Siberil S., Duffy D. Keeping the memory of influenza viruses. Pathol Biol 2010, 58:e79-e86.
2. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25(39-40):6852-6862.
3. Cao J., Wang Y., Song H., Meng Q., Sheng L., Bian T., et al. Hepatitis A outbreaks in China during 2006: application of molecular epidemiology. Hepatol Int 2009, 3(2):356-363.
4. Mathews J.D., McBryde E.S., McVernon J., Pallaghy P.K., McCaw J.M. Prior immunity helps to explain wave-like behaviour of pandemic influenza in 1918-9. BMC Infect Dis 2010, 10:128.
5. Morens D.M., Taubenberger J.K., Fauci A.S. The persistent legacy of the 1918 influenza virus. N Engl J Med 2009, 361(3):225-229.
6. Shen J., Ma J., Wang Q. Evolutionary trends of A(H1N1) influenza virus hemagglutinin since 1918. PLoS ONE 2009, 4(11):e7789.
7. Zhang X. Return and reformation after a century-from 1918 to 2009 H1N1. Protein Cell 2010, 1(5):425-426.
8. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360(25):2605-2615.
9. Michaelis M., Doerr H.W., Cinatl J. An influenza A H1N1 virus revival-pandemic H1N1/09 virus. Infection 2009, 37(5):381-389.
10. Peiris J.S., Poon L.L., Guan Y. Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. J Clin Virol 2009, 45(3):169-173.
11. Zimmer S.M., Burke D.S. Historical perspective-emergence of influenza A (H1N1) viruses. N Engl J Med 2009, 361(3):279-285.
12. Lyndon J.M., Mikhail N.M., Maria R.C., Alexander B.T., Nikolai V.B., Darwyn K., et al. Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J Virol 2000, 74:6015-6020.
13. Wagner R., Matrosovich M.N., Klenk H.D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 2002, 12(3):159-166.
14. Johansson B.E., Bucher D.J., Kilbourne E.D. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 1989, 63(3):1239-1246.
15. Johansson B.E., Kilbourne Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J Virol 1993, 67(10):5721-5723.
16. Couceiro J.N., Paulson J.C., Baum L.G. Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res 1993, 29(2):155-165.
17. Gambaryan A.S., Piskarev V.E., Yamskov I.A., Sakharov A.M., Tuzikov A.B., Bovin N.V., et al. Human influenza virus recognition of sialyloligosaccharides. FEBS Lett 1995, 366(1):57-60.
18. Liu C., Eichelberger M.C., Compans R.W., Air G.M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 1995, 69(2):1099-1106.
19. Matrosovich M.N., Matrosovich T.Y., Gray T., Roberts N.A., Klenk H.D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004, 78(22):12665-12667.
20. Chen H., Wang Y., Liu W., Zhang J., Dong B., Fan X., et al. Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China. Emerg Infect Dis 2009, 15(11):1849-1850.
21. Greenbaum J.A., Kotturi M.F., Kim Y., Oseroff C., Vaughan K., Salimi N., et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 2009, 106(48):20365-20370.
22. Rizzo C., Rota M.C., Bella A., Alfonsi V., Declich S., Caporali M.G., et al. Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period. Vaccine 2010, 28(20):3558-3562.
23. Tang J.W., Tambyah P.A., Wilder-Smith A., Puong K.Y., Shaw R., Barr I.G., et al. Cross-reactive antibodies to pandemic (H1N1) 2009 virus, Singapore. Emerg Infect Dis 2010, 16(5):874-876.
24. Xing Z., Cardona C.J. Preexisting immunity to pandemic (H1N1) 2009. Emerg Infect Dis 2009, 15(11):1847-1849.
25. Arias C.F., Escalera-Zamudio M., Soto-Del Rio Mde L., Cobian-Guemes A.G., Isa P., Lopez S. Molecular anatomy of 2009 influenza virus A (H1N1). Arch Med Res 2009, 40(8):643-654.
26. Sinha N.K., Roy A., Das B., Das S., Basak S. Evolutionary complexities of swine flu H1N1 gene sequences of 2009. Biochem Biophys Res Commun 2009, 390(3):349-351.
27. Wei C.J., Boyington J.C., Dai K., Houser K.V., Pearce M.B., Kong W.P., et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med 2010, 2(24):24ra21.
28. Xu R., Ekiert D.C., Krause J.C., Hai R., Crowe J.E., Wilson I.A. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010, 328(5976):357-360.
29. Zhang W., Qi J., Shi Y., Li Q., Gao F., Sun Y., et al. Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein Cell 2010, 1(5):459-467.
30. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325(5937):197-201.
31. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(20):1945-1952.
32. Lin X., Zhou J., Zhang Y., Wu J., Zhang F., Li Z., et al. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro. Biochem Biophys Res Commun 2009, 390(4):1305-1308.
33. Reddy D. Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir. J Antimicrob Chemother 2010, 65(suppl):ii35-ii40.
34. Sanders D.A. No false start for novel pseudotyped vectors. Curr Opin Biotechnol 2002, 13(5):437-442.
35. Zhang Y., Lin X., Wang G., Zhou J., Lu J., Zhao H., et al. Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses. PLoS ONE 2010, 5(2):e9167.
36. Zhang Y., Lin X., Zhang F., Wu J., Tan W., Bi S., et al. Hemagglutinin and neuraminidase matching patterns of two influenza A virus strains related to the 1918 and 2009 global pandemics. Biochem Biophys Res Commun 2009, 387(2):405-408.
37. Wang S., Parker C., Taaffe J., Solórzano A., García-Sastre A., Lu S. Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 2008, 26(29-30):3626-3633.
38. Taubenberger J.K. Influenza virus hemagglutinin cleavage into HA1, HA2: no laughing matter. Proc Natl Acad Sci U S A 1998, 95(17):9713-9715.
39. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am J Epidemiol 1938, 27:493-497.
40. Tsai C., Caillet C., Hu H., Zhou F., Ding H., Zhang G., et al. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 2009, 27(48):6777-6790.
41. Lemaitre M., Carrat F. Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic. BMC Infect Dis 2010, 10(1):162.
42. McCullers J.A., Van De Velde L.A., Allison K.J., Branum K.C., Webby R.J. Flynn PM. Recipients of vaccine against the 1976 " swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis 2010, 50(11):1487-1492.
43. Del Giudice G., Stittelaar K.J., van Amerongen G., Simon J., Osterhaus A.D., Stohr K., et al. Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci Transl Med 2009, 1(12):12re1.
44. Ge X., Tan V., Bollyky P.L., Standifer N.E., James E.A., Kwok W.W. Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol 2010, 84(7):3312-3319.
45. Labrosse B., Tourdjman M., Porcher R., LeGoff J., de Lamballerie X., Simon F., et al. Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay. PLoS ONE 2010, 5(6):e11036.
46. Rodriguez-Alvarez M., Velasco-Velasco A.M., Alvarez-Anell N.J., Jimenez-Corona M.E., de Leon-Rosales S.P. Identification of seasonal vaccine hemagglutinin subtype 1 (H1) epitopes in Mexican isolates of the new influenza A (H1N1) 2009 virus. Arch Med Res 2009, 40(8):687-692.
47. Tu W., Mao H., Zheng J., Liu Y., Chiu S.S., Qin G., et al. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 2010, 84(13):6527-6535.
48. Valdespino-Gomez J.L., Garcia-Garcia L., de Leon-Rosales S.P. Vaccines against influenza A (H1N1) pandemic. Arch Med Res 2009, 40(8):693-704.
49. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13(3):426-435.
50. Xie H., Liu T.M., Lu X., Wu Z., Belser J.A., Katz J.M., et al. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice. J Infect Dis 2009, 200(12):1874-1883.
51. Chen Q., Kuang H., Wang H., Fang F., Yang Z., Zhang Z., et al. Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes 2009, 38(1):30-38.
52. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22(23-24):2993-3003.
53. Tamura M., Webster R.G., Ennis F.A. Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses. J Virol 1994, 68(6):3499-3504.
54. Ochiai H., Kurokawa M., Matsui S., Yamamoto T., Kuroki Y., Kishimoto C., et al. Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody. J Med Virol 1992, 36(3):217-221.
55. Tamura M., Webster R.G., Ennis F.A. Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry. Virology 1991, 182(1):211-219.
56. Chan M.C., Chan R.W., Yu W.C., Ho C.C., Yuen K.M., Fong J.H., et al. Tropism and innate host responses of the 2009 pandemic H1N1 influenza virus in ex vivo and in vitro cultures of human conjunctiva and respiratory tract. Am J Pathol 2010, 176(4):1828-1840.
57. To K.K., Hung I.F., Li I.W., Lee K.L., Koo C.K., Yan W.W., et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010, 50(6):850-859.
58. Woo P.C., Tung E.T., Chan K.H., Lau C.C., Lau S.K., Yuen K.Y. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies. J Infect Dis 2010, 201(3):346-353.
59. Green S., Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006, 19(5):429-436.